Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
JohnDeere, you can't believe the buys and sells.
Superb announcement. http://www.lse.co.uk/share-regulatory-news.asp?shareprice=ABDP&ArticleCode=ztijx644&ArticleHeadline=Significant_Contract_for_Driving_Robots
A secondary listing on the US Nasdaq exchange has helped raise Chi-Med’s profile, and has given an extra dose of momentum to the London-listed shares as well. Analysts expect this to continue, particularly as the group initiates more late-stage trials for drugs under development. Buy.
miti, I got in about the same time as you although I'd bought a small holding at around 1900. Davey, I wonder if the price is climbing because Christian Hogg has recently talked about HCM becoming a multi billion dollar company. Also wonder how much actually is multi in his view.
http://www.lse.co.uk/DirectorsDeals.asp?shareprice=HCM&share=hutchison_china
Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that the China Food and Drug Administration ("CFDA") has acknowledged acceptance of the New Drug Application ("NDA") for fruquintinib for the treatment of patients with advanced colorectal cancer, which triggers a milestone payment of RMB30.8 million (US$4.5 million) from Lilly to Chi-Med. The NDA is supported by data from the successful FRESCO study, a Phase III pivotal registration trial of fruquintinib in 416 patients with locally advanced or metastatic colorectal cancer ("CRC") in China, which was highlighted in an oral presentation at the American Society of Clinical Oncology Annual Meeting on June 5, 2017.
Analysts at Panmure Gordon Reconfirmed their Past ‘Buy’ rating on Shares Hutchison China Meditech Ltd (LON:HCM), Set a GBX 3530.00 Target Price per Share May 19, 2017 - By Hazel Jackson Hutchison China Meditech Ltd (LON:HCM) Rating Reaffirmed Panmure Gordon now has a GBX 3530.00 target price per share on the 1.89 billion GBP market cap company or 13.23 % upside potential. In an analyst report sent to investors and clients on Thursday morning, Hutchison China Meditech Ltd (LON:HCM) shares have had their Buy Rating reiterated by investment analysts at Panmure Gordon.
Hutchison China MediTech Ltd – (NASDAQ:HCM) received a $30.00 price target from research analysts at Canaccord Genuity in a research note issued on Thursday. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity’s price objective would indicate a potential upside of 52.28% from the stock’s current price.
The UK and USA presentations from last week are now on http://www.chi-med.com/investors/event-information/
London: Tuesday, March 21, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that it will host Research & Development ("R&D") briefings in London and New York to provide an overview of the Company's clinical pipeline of eight novel drug candidates. The events for analysts and investors will take place in London on Wednesday, March 29, and in New York on Thursday, March 30, 2017. The briefing on Wednesday, March 29, 2017 in London will begin with a keynote presentation from Dr Susan Galbraith, Vice President of Oncology Innovative Medicines and Early Development at AstraZeneca. Mr Christian Hogg, Chief Executive Officer; Dr Weiguo Su, Executive Vice President and Chief Scientific Officer; Dr Zhenping Wu, Senior Vice President of Pharmaceutical Sciences; and Dr May Wang, Senior Vice President of Business Development & Strategic Alliances, will be presenting on Chi-Med's research & development and partnering activities. Chi-Med currently has partnerships with AstraZeneca, Eli Lilly and Company and Nestlé Health Science S.A. To register for the London briefing, please contact Dr Marine Perrier by telephone at +44 20 7282 1068 or by email at marine.perrier@citigatedr.co.uk. To register for the New York briefing, please contact Matt Beck by telephone at +1 646 378 2933 or by email at mbeck@troutgroup.com.